HDHL-Biomarkers: Biomarkers for Infant Fat Mass Development and Nutrition (BioFN)

事件：儿童肥胖是一个迅速增长的问题。减肥计划的效果有限，预防是我们遏制这种新流行病的唯一希望。尤其是婴儿脂肪量的发育，对后来的身体脂肪量有长期的影响，从而对代谢健康产生影响。血脂谱可用作脂肪大量发育的生物标记物，并为儿童后期肥胖提供预测生物标记物。世卫组织：BioFN汇集了以下专家：-脂质组学(英国剑桥大学阿尔伯特·库尔曼博士)；-儿科内分泌学(Anita Hokken-Koelea教授，伊拉斯谟大学，NL；英国剑桥大学的David Dunger教授和Ken Ong博士)-系统生物学(Henrik Bjoern Nielsen博士，临床微生物学，DK)-脂代谢(Lars Hellgren博士，丹麦技术大学DK)。BioFN由Albert Koulman博士协调。HOW：BioFN将在两项出生队列研究--索菲亚-冥王星(鹿特丹，NL)和剑桥婴儿生长研究(英国)的样本中使用基于高分辨率质谱仪的脂谱分析，这两项研究都拥有非常精确的身体成分数据。这将使我们能够开发脂肪分布的预测性生物标记物。通过量化膳食对脂肪代谢、肠道微生物代谢和脂肪分布的影响，BioFN将为预防儿童肥胖提供工具。

WHAT: Childhood obesity is a rapidly growing problem. Weight loss programs have limited effects and prevention is our only hope to stem this new epidemic. Infant fat mass development in particular, has long-term effects on later body fat mass and thus metabolic health. Lipid profiles may be used as biomarkers for fat mass development and provide predictive biomarkers for later childhood obesity.WHO:BioFN brings together experts on:- Lipidomics (Dr Albert Koulman, University of Cambridge, UK); - Paediatric endocrinology (Prof Anita Hokken-Koelega, Erasmus University, NL; Prof David Dunger and Dr Ken Ong, University of Cambridge, UK)- Systems biology (Dr Henrik Bjoern Nielsen, Clinical Microbiomics, DK) - Lipid metabolism (Dr Lars Hellgren, Danish Technical University, DK).BioFN is coordinated by Dr Albert Koulman.HOW: BioFN will use high-resolution mass spectrometry based lipid profiling in samples from two birth cohort studies, Sophia-Pluto (Rotterdam, NL) and Cambridge Baby Growth Study (UK) that both have very precise body composition data. This will allow us to develop predictive biomarkers for fat distribution. By quantifying the dietary effect on lipid metabolism, gut microbiome metabolism and fat distribution BioFN will provide tools to prevent of childhood obesity.